ALS publications
Papers and presentations from the ALS program.
All publications and presentations
- PerspectiveRestoring Regulatory Fairness and Reclaiming Biomedical Leadership: ALS, Rare Disease Regulation, and the Future of Regenerative Medicine Journal of the Academy of Public Health View source
- PresentationCSF biomarker correlations with primary outcome in NurOwn® Phase 3 clinical trial 2021 Annual NEALS Meeting View source
- Peer-reviewedEffects of MSC-NTF cells on T and B regulatory cell function in ALS Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration View source
- Peer-reviewedNurOwn®, phase 2, randomized, clinical trial in patients with ALS Neurology View source
- PresentationMolecular characterization of VEGF secretion by MSC-NTF cells (NurOwn®): therapeutic implications in ALS 2019 Annual AAN Meeting View source
- PresentationModulation of CSF caspase-3 in MSC-NTF cells (NurOwn®) in a Phase 2 ALS study: correlations with CSF biomarkers and clinical response 2019 Annual AAN Meeting View source
- PresentationA systematic review of enrichment strategies for current clinical trials in ALS International Symposium on ALS/MND View source
- PresentationMicroRNA changes in the NurOwn® Phase 2 ALS randomized clinical trial: relationship to neuroprotection and innate immunity Annual NEALS Conference View source
- PresentationModulation of CSF miRNAs in ALS Phase 2 study participants treated with MSC-NTF cells (NurOwn®) Annual AAN Meeting View source
- PresentationNurOwn® Phase 2 ALS trial: ALSFRS-R improvement is reflected in subscale domains Annual AAN Meeting View source
- Peer-reviewedSafety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells Clin Transl Med View source
- Peer-reviewedRare combination of myasthenia and motor neuronopathy, responsive to MSC-NTFstem cell therapy Muscle Nerve View source
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.